MA47576A - Composés inhibiteurs d'oga bicyclique - Google Patents
Composés inhibiteurs d'oga bicycliqueInfo
- Publication number
- MA47576A MA47576A MA047576A MA47576A MA47576A MA 47576 A MA47576 A MA 47576A MA 047576 A MA047576 A MA 047576A MA 47576 A MA47576 A MA 47576A MA 47576 A MA47576 A MA 47576A
- Authority
- MA
- Morocco
- Prior art keywords
- bicyclic
- inhibitor compounds
- oga inhibitor
- oga
- compounds
- Prior art date
Links
- 229940126137 O-GlcNAcase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16204834 | 2016-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47576A true MA47576A (fr) | 2020-01-01 |
Family
ID=57570521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047576A MA47576A (fr) | 2016-12-16 | 2017-12-15 | Composés inhibiteurs d'oga bicyclique |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190359609A1 (fr) |
| EP (1) | EP3555094A1 (fr) |
| JP (1) | JP2020503300A (fr) |
| CN (1) | CN110312716A (fr) |
| AU (1) | AU2017378182A1 (fr) |
| CA (1) | CA3044762A1 (fr) |
| MA (1) | MA47576A (fr) |
| WO (1) | WO2018109198A1 (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX381417B (es) | 2014-08-28 | 2025-03-12 | Asceneuron Sa | Inhibidores de glucosidasa. |
| CA3001768C (fr) | 2015-11-02 | 2022-12-13 | Janssen Pharmaceutica Nv | Compose [1,2,4]triazolo[1,5-a]pyridmidine-7-yl |
| JP2019506430A (ja) | 2016-02-25 | 2019-03-07 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| JP6971999B2 (ja) | 2016-02-25 | 2021-11-24 | エースニューロン・ソシエテ・アノニム | ピペラジン誘導体の酸付加塩 |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| CN108884077A (zh) | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| WO2018083101A1 (fr) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | Composés de [1,2,4] triazolo [1,5-a] pyrimidine en tant qu'inhibiteurs de pde2 |
| WO2018083103A1 (fr) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | Composés de [1,2,4]triazolo[1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 |
| KR20190070972A (ko) | 2016-11-02 | 2019-06-21 | 얀센 파마슈티카 엔.브이. | Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 유도체 |
| AU2018223192A1 (en) * | 2017-02-27 | 2019-06-20 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as OGA inhibitors |
| US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
| EP3765458B1 (fr) * | 2018-03-14 | 2023-01-11 | Biogen MA Inc. | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase |
| US11459324B2 (en) | 2018-03-14 | 2022-10-04 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors |
| ES2939043T3 (es) * | 2018-07-31 | 2023-04-18 | Lilly Co Eli | Compuestos de 5-metil-4-fluoro-tiazol-2-ilo |
| CA3110032A1 (fr) | 2018-08-22 | 2020-02-27 | Asceneuron S.A. | Sels d'addition d'acide succinate et fumarate de derives de piperazine utiles en tant qu'inhibiteurs de glycosidase |
| US11795165B2 (en) | 2018-08-22 | 2023-10-24 | Asceneuron Sa | Tetrahydro-benzoazepine glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| WO2020039029A1 (fr) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Composés spiro utilisés en tant qu'inhibiteurs de glycosidases |
| CN113166137B (zh) | 2018-09-19 | 2024-08-16 | 比奥根Ma公司 | O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂 |
| TWI716107B (zh) | 2018-09-26 | 2021-01-11 | 美商美國禮來大藥廠 | 6-氟-2-甲基苯并[d]噻唑-5-基化合物 |
| EP4327814A3 (fr) * | 2018-12-05 | 2024-04-24 | Biogen MA Inc. | Dérivés morpholinyle, pipérazinyle, oxazépanyle et diazépanyle en tant qu'inhibiteurs de o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase |
| KR20220118484A (ko) * | 2019-12-18 | 2022-08-25 | 얀센 파마슈티카 엔.브이. | Oga 억제제 화합물 |
| AU2020409728A1 (en) * | 2019-12-18 | 2022-08-11 | Janssen Pharmaceutica Nv | OGA inhibitor compounds |
| KR102533471B1 (ko) | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
| WO2024081775A1 (fr) | 2022-10-14 | 2024-04-18 | Eli Lilly And Company | Synthèse de composés 6-fluoro-2-méthylbenzo[d] thiazol-5-yle |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103974940B (zh) * | 2011-12-06 | 2016-08-24 | 詹森药业有限公司 | 5-(3-氨基苯基)-5-烷基-5,6-二氢-2h-[1,4]噁嗪-3-胺衍生物 |
| WO2014159234A1 (fr) * | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | Inhibiteurs de glycosidases |
| EP3134413B1 (fr) * | 2014-04-23 | 2019-09-11 | Dart NeuroScience (Cayman) Ltd. | Composés de [1,2,4]triazolo[1,5-a]pyrimidin-7-yle substitués utilisables en tant qu'inhibiteurs de pde2 |
| MX381417B (es) | 2014-08-28 | 2025-03-12 | Asceneuron Sa | Inhibidores de glucosidasa. |
| WO2017035114A1 (fr) * | 2015-08-25 | 2017-03-02 | Janssen Pharmaceutica Nv | Dérivés de benzimidazole utiles à titre d'agonistes inverses de cb-1 |
| CA3001768C (fr) | 2015-11-02 | 2022-12-13 | Janssen Pharmaceutica Nv | Compose [1,2,4]triazolo[1,5-a]pyridmidine-7-yl |
-
2017
- 2017-12-15 EP EP17825805.9A patent/EP3555094A1/fr not_active Withdrawn
- 2017-12-15 MA MA047576A patent/MA47576A/fr unknown
- 2017-12-15 AU AU2017378182A patent/AU2017378182A1/en not_active Abandoned
- 2017-12-15 WO PCT/EP2017/083125 patent/WO2018109198A1/fr not_active Ceased
- 2017-12-15 JP JP2019532020A patent/JP2020503300A/ja active Pending
- 2017-12-15 CN CN201780086726.3A patent/CN110312716A/zh active Pending
- 2017-12-15 CA CA3044762A patent/CA3044762A1/fr not_active Abandoned
- 2017-12-15 US US16/469,685 patent/US20190359609A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017378182A1 (en) | 2019-06-06 |
| EP3555094A1 (fr) | 2019-10-23 |
| US20190359609A1 (en) | 2019-11-28 |
| WO2018109198A1 (fr) | 2018-06-21 |
| CN110312716A (zh) | 2019-10-08 |
| JP2020503300A (ja) | 2020-01-30 |
| CA3044762A1 (fr) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125826T1 (el) | Ενωσεις αναστολεις της βητα-λακταμασης | |
| MA47575A (fr) | Composés inhibiteurs d'oga monocyclique | |
| EP3558322A4 (fr) | Composés benzyl-amide phosphodiamide antiviraux | |
| EP3532069A4 (fr) | Composés aryl-amide phosphodiamide antiviraux | |
| EP3720430A4 (fr) | Composés benzocarbonyle | |
| IL264458B (en) | Cannabis composition | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| EP3464275A4 (fr) | Composés inhibiteurs de l'egfr | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| IL264461A (en) | Cannabis composition | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| MA42919A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| MA42918A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| EP3445750A4 (fr) | Composés thérapeutiques | |
| LT4101855T (lt) | Priešnavikiniai junginiai | |
| PT3523390T (pt) | Utilização de composições à base de tetrafluoropropeno | |
| EP3436003A4 (fr) | Composés bicycliques antidiabétiques | |
| EP3317241A4 (fr) | Composés inhibiteurs thérapeutiques | |
| EP3562487A4 (fr) | Composés inhibiteurs des métalloenzymes | |
| EP3560926A4 (fr) | COMPOSÉ INHIBITEUR DE Brk | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac |